Working with TipRanks
Follow Us
Stocks
ETFs
Options
Crypto
Research Tools
Calendars
Calculators
Education
About Us
Working with TipRanks
Follow Us
Day One Biopharmaceuticals (DAWN)
NASDAQ:DAWN
RESEARCH TOOLSreports
Day One Biopharmaceuticals (DAWN) Stock Price & Analysis
98 Followers
DAWN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$9.67 - $25.77
Previous Close$12.26
Volume400.93K
Average Volume (3M)839.92K
Market Cap
$1.07B
Enterprise Value$662.12M
Total Cash (Recent Filing)$405.54M
Total Debt (Recent Filing)$514.00K
Price to Earnings (P/E)-5.4
Beta-0.52
Next Earnings
Mar 04, 2024EPS Estimate
-$0.57Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.28
Shares Outstanding87,042,933
10 Day Avg. Volume487,088
30 Day Avg. Volume839,923
Standard Deviation0.38
R-Squared0.06
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)2.74
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-7.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue181.45
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-5.22
Forecast
1Y Price Target
$36.00Price Target Upside196.05% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering8
Day One Biopharmaceuticals News
Ownership Overview
0.00% Insiders
19.12% Mutual Funds
60.19% Other Institutional Investors
20.69% Public Companies and
Individual Investors
DAWN FAQ
What was Day One Biopharmaceuticals’s price range in the past 12 months?
Day One Biopharmaceuticals lowest stock price was $9.67 and its highest was $25.77 in the past 12 months.
What is Day One Biopharmaceuticals’s market cap?
Currently, no data Available
When is Day One Biopharmaceuticals’s upcoming earnings report date?
Day One Biopharmaceuticals’s upcoming earnings report date is Mar 04, 2024 which is in 90 days.
How were Day One Biopharmaceuticals’s earnings last quarter?
Day One Biopharmaceuticals released its earnings results on Nov 06, 2023. The company reported -$0.54 earnings per share for the quarter, beating the consensus estimate of -$0.586 by $0.046.
Is Day One Biopharmaceuticals overvalued?
According to Wall Street analysts Day One Biopharmaceuticals’s price is currently Undervalued.
Does Day One Biopharmaceuticals pay dividends?
Day One Biopharmaceuticals does not currently pay dividends.
What is Day One Biopharmaceuticals’s EPS estimate?
Day One Biopharmaceuticals’s EPS estimate is -$0.57.
How many shares outstanding does Day One Biopharmaceuticals have?
Day One Biopharmaceuticals has 87,042,930 shares outstanding.
What happened to Day One Biopharmaceuticals’s price movement after its last earnings report?
Day One Biopharmaceuticals reported an EPS of -$0.54 in its last earnings report, beating expectations of -$0.586. Following the earnings report the stock price went up 1.395%.
Which hedge fund is a major shareholder of Day One Biopharmaceuticals?
Among the largest hedge funds holding Day One Biopharmaceuticals’s share is RA Capital Management. It holds Day One Biopharmaceuticals’s shares valued at 96M.
---
Day One Biopharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$36.00 (196.05% Upside)
$36.00 (196.05% Upside)
Blogger Sentiment
Bullish
DAWN Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 71.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $15.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 0.8%
Last 30 Days ▲ 1.5%
Last 30 Days ▲ 1.5%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-42.22%
12-Months-Change
Fundamentals
Return on Equity
-46.37%
Trailing 12-Months
Asset Growth
8.46%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Day One Biopharmaceuticals
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The lead product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, kinase inhibitor.
---
Top 5 ETFs holding DAWN
Vanguard Total Stock Market ETF
$22.87M
Vanguard Health Care ETF
$1.76M
Fidelity Nasdaq Composite Index ETF
$611.45K
Schwab U.S. Broad Market ETF
$357.46K
Vanguard Russell 3000 ETF
$49.84K
Up to five ETFs with an Outperform Smart Score that hold DAWN. The ETFs are listed according to market value of DAWN within the ETF
---